Monitor for potential downward pressure on SNOA stock price due to significant dilution and the 25% discount pricing, which may signal weak demand. The capital raise provides near-term liquidity but reflects challenging market conditions for this micro-cap company.
Executive Summary
Sonoma Pharmaceuticals priced a $4 million public offering of 2,962,962 units, each consisting of one share of common stock (or pre-funded warrant) and one warrant to purchase a share of common stock, at $1.35 per unit. The offering was priced at a 25% discount to the prior closing price of $1.80 and results in approximately 163% dilution of existing shares. Net proceeds are expected to be $3.55 million, used for working capital and general corporate purposes.
Key Financial Metrics
Key Facts
- Offering raised $3.999 million in gross proceeds by selling 2,962,962 units at $1.35 per unit
- Offering priced at $1.35, a 25% discount to the prior closing price of $1.80 on April 23, 2026
- Dilution is approximately 163% based on 1,822,838 shares outstanding before the offering and 4,785,800 shares expected after
- Net proceeds estimated at $3.55 million after underwriting discounts and expenses, to be used for working capital and general corporate purposes
- Underwriters are Dawson James Securities, Inc., with a 7.5% underwriting discount ($299,999) and a 90-day lock-up agreement
Financial Impact
Raises $3.999 million gross ($3.55 million net) while diluting existing shareholders by approximately 163%
Risk Factors
- Significant shareholder dilution of approximately 163%
- 25% discount to market price suggests weak investor demand
- Proceeds are relatively small ($3.55 million net) for a public company, indicating ongoing funding challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001683168-26-003212 |
| Document: 0001683168-26-003212-index-headers.html | 0001683168-26-003212 |
| Document: 0001683168-26-003212-index.html | 0001683168-26-003212 |
| Document: 0001683168-26-003212.txt | 0001683168-26-003212 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.22 $1.16 | ▼ −4.92% | ▼ −4.49% | $1.12 (−8.20%) |
Jun 18, 2026 18w ago | 8-K | $1.16 $1.14 | ▲ +1.72% | ▲ +0.27% | $1.12 (+3.45%) |
Jun 18, 2026 18w ago | 424B5 | $1.16 $1.14 | ▲ +1.72% | ▲ +0.27% | $1.12 (+3.45%) |
Apr 27, 2026 26w ago | 424B4 | $1.11 $1.04 | ▲ +6.31% | ▲ +5.82% | $1.12 (−0.90%) |
Apr 17, 2026 27w ago | S-1 | $2.65 $2.25 | ▼ −15.09% | ▼ −14.44% | $1.12 (−57.74%) |
Apr 9, 2026 28w ago | 8-K | $2.41 $2.28 | ▼ −5.39% | ▼ −5.33% | $1.12 (−53.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers